Lipocine

LPCN · NASDAQ · Pharmaceutical Preparations

Lipocine (LPCN) · oqro.io/stocks/LPCN · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.

How this filing works

Ask Claude or ChatGPT about these filings. Connect OQRO in a minute, then ask things like “which insiders bought this week?”

Want the short version?

Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.

Explain this page What did insiders at LPCN buy and sell in the last 90 days?Which members of Congress and which funds traded LPCN recently?

Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.

Insider trades around earnings

9 open-market purchases and 0 open-market sales by insiders of LPCN between Feb 8, 2026 and today, placed against the company's last 4 earnings releases. The latest on file was filed Nov 5, 2026. The data provider lists the next release for Mar 8, 2027; that date may change.

PurchaseSale30 days before a release30 days after

Trades in the 30 days around each of the last earnings releases
Earnings release	30 days before	On the day	30 days after
Nov 5, 2026	None	None	2 purchases
Aug 4, 2026	None	None	None
May 7, 2026	1 purchase	None	None
Mar 10, 2026	None	None	4 purchases

Mahesh V. Patel, Chief Executive Officer, Nov 13, 2026, about $40K. Bought 8 days after the company's previous earnings release on 2026-11-05Form 4
Mahesh V. Patel, Chief Executive Officer, Nov 12, 2026, about $39K. Bought 7 days after the company's previous earnings release on 2026-11-05Form 4
John W. Higuchi, Director, Sep 30, 2026, about $36K. Bought 36 days before the company's next earnings release on 2026-11-05Form 4
John W. Higuchi, Director, Sep 29, 2026, about $19K. Bought 37 days before the company's next earnings release on 2026-11-05Form 4

Companies set trading windows, which usually close shortly before results and reopen after them, and insiders may trade under 10b5-1 plans adopted months earlier. A date alone does not show what a person knew or why they traded. Past release dates are the dates the company filed its 8-K with Item 2.02. An upcoming date, when one is mentioned, comes from the data provider's earnings calendar (Finnhub): it is not a company filing, it is not estimated by OQRO, and it may change. Open-market purchases and sales as reported on Form 4. Largest purchases around earnings, all companies

Insider trades · 17

Including 8 routine filings (option exercises, tax withholding, grants, gifts). Open-market trades only

Mahesh V. PatelChief Executive Officer

Filed yesterday

Bought

~$79Kacross 2 transactionsin 1 filing

Traded Nov 12 – Nov 13, 2026 · largest single transaction ~$40K

Show all 2 transactions

Nov 12, 2026~$39K · 25K sh @ $1.58
Details Official record
Nov 13, 2026~$40K · 25K sh @ $1.60
Details Official record

John W. HiguchiDirector

Filed 6w ago

Bought

~$82Kacross 3 transactionsin 2 filings

Traded Sep 28 – Sep 30, 2026 · largest single transaction ~$36K

Show all 3 transactions

Sep 30, 2026~$36K · 16K sh @ $2.23
Details Official record

Insider filing

Michael GrissingerDirector

Filed 3mo ago

2,000Derivative units · @ $2.11

Traded Aug 3 · filed 4 days later

Compensation award — excluded from discretionary-purchase analysis.

More Official record

Insider filing

Mahesh V. PatelChief Executive Officer

Filed 5mo ago

53KDerivative units · @ $2.49

Traded Jun 29 · filed 1 day later

Compensation award — excluded from discretionary-purchase analysis.

More Official record

Insider filing

Jill M. JeneDirector

Filed 5mo ago

1,764Derivative units · @ $2.19

Traded Jun 3 · filed 1 day later

Compensation award — excluded from discretionary-purchase analysis.

More Official record

Insider filing

John W. HiguchiDirector

Filed 5mo ago

1,764Derivative units · @ $2.19

Traded Jun 3 · filed 1 day later

Compensation award — excluded from discretionary-purchase analysis.

More Official record

Insider filing

Richard Dana OnoDirector

Filed 5mo ago

1,764Derivative units · @ $2.19

Traded Jun 3 · filed 1 day later

Compensation award — excluded from discretionary-purchase analysis.

More Official record

John W. HiguchiDirector

Filed 7mo ago

Bought

~$333Kacross 2 transactionsin 2 filings

Traded Apr 6 – Apr 7, 2026 · largest single transaction ~$252K

Show all 2 transactions

Apr 7, 2026~$81K · 40K sh @ $2.03
Details Official record

Insider buying

Mahesh V. PatelChief Executive Officer

Filed 7mo ago

Bought

~$51K25K sh @ $2.03

10 days before an 8-KTraded Apr 6 · filed the same day

Since the trade −11.9% · S&P 500 +14.5% · to Nov 13

The CEO of Lipocine paid $51K out of pocket for Lipocine shares. 1 other person at Lipocine bought some too, in the same month. Shares held went up 18% with this purchase.

Insider buying

Mahesh V. PatelChief Executive Officer

Filed 8mo ago

Bought

~$51K25K sh @ $2.02

14 days before an 8-KTraded Apr 2 · filed the same day

Since the trade −16.6% · S&P 500 +15.0% · to Nov 13

The CEO of Lipocine paid $51K out of pocket for Lipocine shares. 1 other person at Lipocine bought some too, in the same month. Shares held went up 23% with this purchase.

Insider filing

Mahesh V. PatelChief Executive Officer

Filed 10mo ago